Axel Grothey, MD, West Cancer Center, University of Tennessee

Articles

Educational Tools for Possible Drug-Induced ILD

June 30th 2020

Management of Patients Who Develop ILD

June 30th 2020

Changes in Treatment Goals due to Drug Induced ILD

June 30th 2020

Risk of ILD as a Class Effect and Identifying ILD

June 30th 2020

Risks for Developing ILD in Gastrointestinal Cancer Studies

June 30th 2020

Role of Antibody Drug Conjugates and Personal Experience

June 30th 2020

Patient Management and Educational Tools for ILD

June 30th 2020

Identifying Drug-Induced ILD

June 30th 2020

Rate of ILD and Monitoring Parameters

June 30th 2020

Personal Experience with Drug-Induced ILD

June 30th 2020

Potential Risk of Drug-Induced Interstitial Lung Disease

June 30th 2020

Patient Management upon Developing ILD and Education

June 30th 2020

Patient Factors for Developing ILD and Personal Experience

June 30th 2020

Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

June 30th 2020

Managing Patient Symptoms and Clinician Education

June 30th 2020

CDK 4/6 Inhibitors and Identifying ILD in Patients

June 30th 2020

Rate and Class Effect of ILD with Antibody Drug Conjugates

June 30th 2020

Use of Antibody Drug Conjugates and Potential for ILD

June 30th 2020

Changes in Cancer Treatment and Management of ILD

June 30th 2020

Risks for Developing ILD and Personal Experience

June 30th 2020

NEXT PAGE
PREVIOUS PAGE